secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0000950170-24-110462
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics names James Cassella Chief Development Officer; CMO David Clark departs
--------------------------------------------------------------------------------

- James Cassella appointed CDO effective Sept 30, 2024; he resigned from the Board on that date.
- David Clark stepped down as CMO effective Sept 27, 2024, to care for a family member; will consult at $400/hour.
- Cassella has 35+ years CNS drug development experience, including CDO at Concert Pharmaceuticals and FDA approval of Leqselvi.
- Company is advancing Haduvio for IPF cough and refractory chronic cough; pivotal program and regulatory submission planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/trvi-20240927.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-110462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer